Beranda › Poliradikuloneuropati Demielinasi Inflamasi Kronis › Pennsylvania
Uji klinis Poliradikuloneuropati Demielinasi Inflamasi Kronis di Pennsylvania
6 studi untuk Poliradikuloneuropati Demielinasi Inflamasi Kronis mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Site Number - 1616, Philadelphia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07032662A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- Penn Medicine University City, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07091630A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Perelman Center for Advanced Medicine, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06920004A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Penn State Health Milton South Hershey Medical Center- Site Number : 8400042, Hershey
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06290141Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
- Investigational Site, Swiftwater
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06968975A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Penn Blood Disorders Program - Hospital of The University of Pennsylvania, Philadelphia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT06798012Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.